MAM
AGRX

Meeder Asset Management’s Agile Therapeutics AGRX Stock Holding History

Meeder Asset Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3
Closed -$2.75K – 1732
2018
Q2 		$2.75K Buy
3
+2
+200% +$7.02K ﹤0.01% 1372
2018
Q1 		$3K Hold
1
– – ﹤0.01% 1342
2017
Q4 		$5K Hold
1
– – ﹤0.01% 1332
2017
Q3 		$7K Buy
+1
New +$7.68K ﹤0.01% 1177
2017
Q2 		– Sell
-1
Closed -$6.92K – 1573
2017
Q1 		$6K Buy
+1
New +$5.03K ﹤0.01% 1031
2016
Q4 		– Hold
0
– – – 864

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Meeder Asset Management's AGRX Position: Q3 2018 in Review

Meeder Asset Management sold out of Agile Therapeutics (AGRX) in Q3 2018, closing a stake of 3 shares — an estimated $2.75K sold.

Meeder Asset Management first reported a position in AGRX in Q1 2017 and held it in 5 quarters. The position peaked at $7K in Q3 2017. 29 funds tracked by Wall St. Rank hold AGRX as of Q3 2018.

  • Meeder Asset Management reported no remaining Agile Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Meeder Asset Management sold 3 Agile Therapeutics shares in Q3 2018, an estimated $2.75K.
  • Meeder Asset Management first reported a position in Agile Therapeutics in Q1 2017 and held it in 5 quarters.
  • Meeder Asset Management's Agile Therapeutics position peaked at $7K in Q3 2017.
  • 29 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2018.

Based on Meeder Asset Management's 13F filing for Q3 2018, filed 2 Nov 2018.